ATS
ADPT icon

Ashton Thomas Securities’s Adaptive Biotechnologies ADPT Stock Holding History

Ashton Thomas Securities’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,685
Closed -$34.2K – 271
2024
Q3 		$34.2K Buy
+6,685
New +$29.1K 0.01% 496

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Ashton Thomas Securities's ADPT Position: Q4 2024 in Review

Ashton Thomas Securities sold out of Adaptive Biotechnologies (ADPT) in Q4 2024, closing a stake of 6,685 shares — an estimated $34.2K sold.

Ashton Thomas Securities first reported a position in ADPT in Q3 2024 and held it in 1 quarter. The position peaked at $34.2K in Q3 2024. 207 funds tracked by Wall St. Rank hold ADPT as of Q4 2024.

  • Ashton Thomas Securities reported no remaining Adaptive Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • Ashton Thomas Securities sold 6,685 Adaptive Biotechnologies shares in Q4 2024, an estimated $34.2K.
  • Ashton Thomas Securities first reported a position in Adaptive Biotechnologies in Q3 2024 and held it in 1 quarter.
  • Ashton Thomas Securities's Adaptive Biotechnologies position peaked at $34.2K in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2024.

Based on Ashton Thomas Securities's 13F filing for Q4 2024, filed 11 Feb 2025.